Figure 1 from Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study

2026 Open access

Read full text
Authors: Marc R. Pelletier, Jie Yang, Mukta Joshi, Angelo L. Grauel, Cara Abecunas, Maria‐Athina Altzerinakou, Zheng Zhou, Xiaoping Zhu, Kirk Clark, Li Li, Li‐Yuan Bai, Michèle Milella
+18 more Teresa Mercade Macarulla, David Wai-Meng Tai, Bruno Bockorny, Peter Grell, Shivan Sivakumar, Mark Ka Wong, Cheng Ean Chee, Thomas Aparicio, Gerald W. Prager, Geraldine Bostel, Brigitte Schiessl, Heiko Maacke, Glenn Dranoff, Alice Tsang Shaw, Claire Fabre, Jennifer Mataraza, Shiva Malek, Viviana Cremasco
DOI: 10.1158/1078-0432.33775723
Cited by: 1

Abstract

Survival outcome. Kaplan–Meier plot of (A) time to PFS per RECIST 1.1 and (B) OS.

Publication details

Publisher
American Association for Cancer Research (AACR)
Publication date
15 September 2026